Single antiplatelet therapy after percutaneous coronary intervention in patients allergic to aspirin

Abstract

Dual antiplatelet therapy including aspirin and a P2Y12 ADP receptor antagonist is given after percutaneous coronary intervention to avoid catastrophic complication of stent thrombosis. Dual antiplatelet therapy is associated with increased bleeding risk and may not be tolerated by many patients. This article presents the patients, which had to be given single antiplatelet therapy after percutaneous coronary intervention and discusses the possible factors responsible for the success of single antiplatelet therapy strategy in these patients, in the current era of newer antiplatelet agents and coronary stents.

Keywords: Antiplatelet therapy; Clopidogrel; PCI; Ticagrelor.